Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OPEN CLINICAL-TRIAL ON THE SIGMA-LIGAND PANAMESINE IN PATIENTS WITH SCHIZOPHRENIA
Autore:
FRIEBOES RM; MURCK H; WIEDEMANN K; HOLSBOER F; STEIGER A;
Indirizzi:
MAX PLANCK INST PSYCHIAT,INST CLIN,KRAEPELINSTR 10 D-80804 MUNICH GERMANY
Titolo Testata:
Psychopharmacology
fascicolo: 1, volume: 132, anno: 1997,
pagine: 82 - 88
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECEPTOR LIGAND; ANTIPSYCHOTIC-DRUGS; BINDING-SITES; RATING-SCALE; PHENCYCLIDINE; BRAIN; CLASSIFICATION; HALOPERIDOL; BMY-14802; OPIATES;
Keywords:
PANAMESINE; SIGMA LIGAND; SCHIZOPHRENIA; ATYPICAL ANTIPSYCHOTIC DRUG; EXTRAPYRAMIDAL SYMPTOMS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
R.M. Frieboes et al., "OPEN CLINICAL-TRIAL ON THE SIGMA-LIGAND PANAMESINE IN PATIENTS WITH SCHIZOPHRENIA", Psychopharmacology, 132(1), 1997, pp. 82-88

Abstract

The sigma (a) receptor has been proposed as a target of neuroleptic drugs, Preclinical data suggest that panamesine (EMD 57445), a novel sigma ligand, has antipsychotic effects and is free of side effects related to the extrapyramidal motoric system (EPMS), Here we report the results of an exploratory study aimed at determining the appropriate dose range and the safety of panamesine in patients with an acute episodeof schizophrenia. The first trial with four patients revealed insufficient clinical efficacy of a protocol where the daily dosage was increased stepwise from 7.5 mg during week 1, up to 30 mg during weeks 3 and 4. In a second set of trials, 12 patients received 15 mg at the beginning, this being increased up to 60 mg/day within 3 days and then maintained at this level for 4 weeks. As assessed by a decrease in the Brief Psychiatric Rating Scale score by at least 50%, five patients werejudged as responders, whereas six patients showed only a slight improvement, and one deteriorated. Moreover, intent-to-treat analysis showed significant improvement in psychometric variables. In all patients prolactin levels increased during treatment, probably due to an active metabolite with weak dopamine-2-receptor antagonistic effects. No major side effects occurred, and in particular, no EPMS symptoms were seen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 10:42:24